Literature DB >> 7975854

Influence of smoking on immunological responses to hepatitis B vaccine.

A P Winter1, E A Follett, J McIntyre, J Stewart, I S Symington.   

Abstract

When 115 health-care workers participated in a study that monitored their serological responses to hepatitis B vaccine at regular intervals, it was found that smoking significantly affected their antibody titre responses adversely. The study group was randomly allocated into two comparable groups that received hepatitis B vaccine either in a rapid schedule (vaccination at 0, 1, 2 and 12 months) or a standard schedule-most commonly used worldwide-(vaccination at 0, 1, and 6 months). A significantly higher proportion of smokers, in both schedules, failed to seroconvert and to achieve higher antibody levels at month 3 (p = 0.01) and at month 13 (p = 0.0003). At month 7 a similar pattern was noted in smokers following the standard vaccination schedule (p < or = 0.05), but not in those following the rapid schedule.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7975854     DOI: 10.1016/0264-410x(94)90283-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  21 in total

Review 1.  Systems immunogenetics of vaccines.

Authors:  Michael Mooney; Shannon McWeeney; Rafick-Pierre Sékaly
Journal:  Semin Immunol       Date:  2013-07-22       Impact factor: 11.130

Review 2.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

3.  Hepatitis B vaccination in HIV-infected youth: a randomized trial of three regimens.

Authors:  Patricia M Flynn; Coleen K Cunningham; Bret Rudy; Craig M Wilson; Bill Kapogiannis; Carol Worrell; James Bethel; Dina Monte; Kelly Bojan
Journal:  J Acquir Immune Defic Syndr       Date:  2011-04       Impact factor: 3.731

4.  Combination of TLR8 and TLR4 agonists reduces the degrading effects of nicotine on DC-NK mediated effector T cell generation.

Authors:  Mahyar Nouri-Shirazi; Saba Tamjidi; Erika Nourishirazi; Elisabeth Guinet
Journal:  Int Immunopharmacol       Date:  2018-05-24       Impact factor: 4.932

Review 5.  New directions in nicotine vaccine design and use.

Authors:  Paul R Pentel; Mark G LeSage
Journal:  Adv Pharmacol       Date:  2014

6.  Randomized trial to determine safety and immunogenicity of two strategies for hepatitis B vaccination in healthy urban adolescents in the United States.

Authors:  Coleen K Cunningham; Bret J Rudy; Jiahong Xu; James Bethel; Bill G Kapogiannis; Sushma Ahmad; Craig M Wilson; Patricia M Flynn
Journal:  Pediatr Infect Dis J       Date:  2010-06       Impact factor: 2.129

7.  Use of Tumor Necrosis Factor-α Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease.

Authors:  Antonius T Otten; Arno R Bourgonje; Petra P Horinga; Hedwig H van der Meulen; Eleonora A M Festen; Hendrik M van Dullemen; Rinse K Weersma; Coretta C van Leer-Buter; Gerard Dijkstra; Marijn C Visschedijk
Journal:  Front Immunol       Date:  2022-07-05       Impact factor: 8.786

8.  Cigarette smoke exposure inhibits contact hypersensitivity via the generation of platelet-activating factor agonists.

Authors:  Ravi P Sahu; Irina Petrache; Mary J Van Demark; Badri M Rashid; Jesus A Ocana; Yuxuan Tang; Qiaofang Yi; Matthew J Turner; Raymond L Konger; Jeffrey B Travers
Journal:  J Immunol       Date:  2013-01-25       Impact factor: 5.422

Review 9.  Vaccinomics and personalized vaccinology: is science leading us toward a new path of directed vaccine development and discovery?

Authors:  Gregory A Poland; Richard B Kennedy; Inna G Ovsyannikova
Journal:  PLoS Pathog       Date:  2011-12-29       Impact factor: 6.823

10.  Comparison of Accelerated and Standard Hepatitis B Vaccination Schedules in High-Risk Healthy Adults: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Hui Jin; Zhaoying Tan; Xuefeng Zhang; Bei Wang; Yueyuan Zhao; Pei Liu
Journal:  PLoS One       Date:  2015-07-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.